Feng Teng1, Lingling Meng2, Fuhai Zhu3, Gang Ren3. 1. Department of Radiation Oncology, China-Japan Friendship Hospital, Beijing, China. 2. Department of Radiotherapy, First Medical Center of Chinese PLA General Hospital, Beijing, China. 3. Department of Radiotherapy, Air Force Medical Center of PLA, Beijing, China.
Abstract
BACKGROUND: This dosimetric study on locally advanced pancreatic cancer (LAPC) and the surrounding gastrointestinal organs at risk (OARs) aimed at exploring the potential of further improving the internal dose and reducing the fractionation number by concurrent hypofractionated simultaneous integrated boost (SIB) radiotherapy using helical tomotherapy (HT). METHODS: We collected computed tomography positioning images from a LAPC study of 17 consecutive patients. Gross tumor volume (GTV)1, GTV2, and GTV3 were defined as the GTV minus a margin of 3, 6, and 9 mm from the external part in all directions, respectively. Under the same physical parameters and limited dose on normal organs, each case had 4 sets of SIB radiotherapy plans. Upon dose escalation, we statistically analyzed the difference of dosimetric parameters received by the OARs between group A [planning target volume (PTV)/GTV=50 Gy/70 Gy] and the other groups. According to the equivalent bioradiotherapy formula, we calculated the hypofractionated standard dose by converting the average tolerated dose of each OAR with the corresponding number of fractions. Then, we compared the dose and volume parameters of the gastrointestinal tract from the less-than-20-fraction modes with the corresponding gastrointestinal hypofractionated standard dose. RESULTS: For dose escalation, although there were a few differences in the parameters of the OAR between group A and group D, all OAR doses of group D (PTV/GTV/GTV1/GTV2/GTV3=50 Gy/70 Gy/80 Gy/90 Gy/100 Gy) were within the limited dose range. In the hypofractionated mode, there was a statistically significant difference between the gastrointestinal dose-volume parameters and the dose-limiting reference standard when the fraction number was less than 14 or 15 for group A or D, respectively. CONCLUSIONS: The dose of the internal target can be increased to 100 Gy with 15 fractions in the hypofractionated SIB radiotherapy for LAPC with HT. The corresponding tolerance dose of OARs may also be acceptable. 2021 Journal of Gastrointestinal Oncology. All rights reserved.
BACKGROUND: This dosimetric study on locally advanced pancreatic cancer (LAPC) and the surrounding gastrointestinal organs at risk (OARs) aimed at exploring the potential of further improving the internal dose and reducing the fractionation number by concurrent hypofractionated simultaneous integrated boost (SIB) radiotherapy using helical tomotherapy (HT). METHODS: We collected computed tomography positioning images from a LAPC study of 17 consecutive patients. Gross tumor volume (GTV)1, GTV2, and GTV3 were defined as the GTV minus a margin of 3, 6, and 9 mm from the external part in all directions, respectively. Under the same physical parameters and limited dose on normal organs, each case had 4 sets of SIB radiotherapy plans. Upon dose escalation, we statistically analyzed the difference of dosimetric parameters received by the OARs between group A [planning target volume (PTV)/GTV=50 Gy/70 Gy] and the other groups. According to the equivalent bioradiotherapy formula, we calculated the hypofractionated standard dose by converting the average tolerated dose of each OAR with the corresponding number of fractions. Then, we compared the dose and volume parameters of the gastrointestinal tract from the less-than-20-fraction modes with the corresponding gastrointestinal hypofractionated standard dose. RESULTS: For dose escalation, although there were a few differences in the parameters of the OAR between group A and group D, all OAR doses of group D (PTV/GTV/GTV1/GTV2/GTV3=50 Gy/70 Gy/80 Gy/90 Gy/100 Gy) were within the limited dose range. In the hypofractionated mode, there was a statistically significant difference between the gastrointestinal dose-volume parameters and the dose-limiting reference standard when the fraction number was less than 14 or 15 for group A or D, respectively. CONCLUSIONS: The dose of the internal target can be increased to 100 Gy with 15 fractions in the hypofractionated SIB radiotherapy for LAPC with HT. The corresponding tolerance dose of OARs may also be acceptable. 2021 Journal of Gastrointestinal Oncology. All rights reserved.
Authors: Nima Nabavizadeh; Anna O Simeonova; Joseph G Waller; Jeanna L Romer; Debra L Monaco; David A Elliott; James A Tanyi; Martin Fuss; Charles R Thomas; John M Holland Journal: Med Dosim Date: 2014-05-23 Impact factor: 1.482
Authors: Rachit Kumar; Aaron T Wild; Mark A Ziegler; Ted K Hooker; Samson D Dah; Phuoc T Tran; Jun Kang; Koren Smith; Jing Zeng; Timothy M Pawlik; Erik Tryggestad; Eric Ford; Joseph M Herman Journal: Med Dosim Date: 2013-03-27 Impact factor: 1.482
Authors: Daniel R Wahl; Matthew H Stenmark; Yebin Tao; Erqi L Pollom; Elaine M Caoili; Theodore S Lawrence; Matthew J Schipper; Mary Feng Journal: J Clin Oncol Date: 2015-11-30 Impact factor: 44.544
Authors: Joe Y Chang; Suresh Senan; Marinus A Paul; Reza J Mehran; Alexander V Louie; Peter Balter; Harry J M Groen; Stephen E McRae; Joachim Widder; Lei Feng; Ben E E M van den Borne; Mark F Munsell; Coen Hurkmans; Donald A Berry; Erik van Werkhoven; John J Kresl; Anne-Marie Dingemans; Omar Dawood; Cornelis J A Haasbeek; Larry S Carpenter; Katrien De Jaeger; Ritsuko Komaki; Ben J Slotman; Egbert F Smit; Jack A Roth Journal: Lancet Oncol Date: 2015-05-13 Impact factor: 41.316
Authors: Jiayi Huang; John M Robertson; Hong Ye; Jeffrey Margolis; Laura Nadeau; Di Yan Journal: Int J Radiat Oncol Biol Phys Date: 2011-11-16 Impact factor: 7.038
Authors: Joseph M Herman; Daniel T Chang; Karyn A Goodman; Avani S Dholakia; Siva P Raman; Amy Hacker-Prietz; Christine A Iacobuzio-Donahue; Mary E Griffith; Timothy M Pawlik; Jonathan S Pai; Eileen O'Reilly; George A Fisher; Aaron T Wild; Lauren M Rosati; Lei Zheng; Christopher L Wolfgang; Daniel A Laheru; Laurie A Columbo; Elizabeth A Sugar; Albert C Koong Journal: Cancer Date: 2014-12-23 Impact factor: 6.860
Authors: Anna Wilkins; Helen Mossop; Isabel Syndikus; Vincent Khoo; David Bloomfield; Chris Parker; John Logue; Christopher Scrase; Helen Patterson; Alison Birtle; John Staffurth; Zafar Malik; Miguel Panades; Chinnamani Eswar; John Graham; Martin Russell; Peter Kirkbride; Joe M O'Sullivan; Annie Gao; Clare Cruickshank; Clare Griffin; David Dearnaley; Emma Hall Journal: Lancet Oncol Date: 2015-10-28 Impact factor: 41.316
Authors: Zhan Shi; Ju Yang; Weiwei Kong; Xin Qiu; Changchang Lu; Juan Liu; Baorui Liu; Juan Du Journal: Front Oncol Date: 2022-03-01 Impact factor: 6.244
Authors: Elisa Meldolesi; Giuditta Chiloiro; Roberta Giannini; Roberta Menghi; Roberto Persiani; Barbara Corvari; Claudio Coco; Stefania Manfrida; Carlo Ratto; Viola De Luca; Luigi Sofo; Sara Reina; Antonio Crucitti; Valeria Masiello; Nicola Dinapoli; Vincenzo Valentini; Maria Antonietta Gambacorta Journal: Cancers (Basel) Date: 2022-03-24 Impact factor: 6.639